Barriers to Value-Based Contracts for Innovative Medicines
PhRMA Member Survey Results
Health care stakeholders from across the system are increasingly moving toward payment approaches that better recognize value. Biopharmaceutical companies and payers, for example, are working together to share risk by more closely tying payment for medicines to the outcomes they deliver to patients. Yet despite growing interest in these innovative approaches to payment, according to a recent survey, biopharmaceutical companies express concern that current regulatory and operational barriers are limiting the number and scope of value-based contracts, also referred to as results-based contracts.